Literature DB >> 8874266

Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets.

B W Böttiger1, J Motsch, J Dörsam, U Mieck, A Gries, J Weimann, E Martin.   

Abstract

Acute massive pulmonary embolism increases pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR), which may lead to early right ventricular failure and subsequent cardiocirculatory deterioration. Inhaled nitric oxide (NO) selectively dilates pulmonary vessels in vivo. Thus, inhaled NO may be useful in preventing cardiocirculatory deterioration following pulmonary embolism. We investigated the effects of inhaled NO in the acute phase of massive pulmonary microembolism in 10 anesthetized and mechanically ventilated piglets (body weight, 18 +/- 2 kg). Microspheres of 300-microns diameter were injected i.v. in an amount sufficient to initially increase mean PAP to 45 mm Hg. Forty-five minutes after pulmonary embolization, the pretreatment control values were recorded. Thereafter, the piglets inhaled 40 ppm NO, and subsequently 80 ppm NO. When 40 ppm NO was inhaled, there was a significant decrease in systolic PAP (-10.3%; 44.5 +/- 2.2 to 39.9 +/- 2.4 mm Hg; p < 0.05) and mean PAP (-9.4%; 32.9 +/- 1.3 to 29.8 +/- 1.3 mm Hg; p < 0.05). PVR was changed by -13.6% (p = 0.07). Administration of 80 ppm NO resulted in a significant decrease in systolic PAP (-12.6%; to 38.9 +/- 1.9 mm Hg; p < 0.05), mean PAP (-11.9%; to 29.0 +/- 1.4 mm Hg; p < 0.05), and PVR (-19.4%; p < 0.05) compared with pretreatment values. Discontinuation of NO inhalation was associated with an immediate return to pretreatment values. Systemic hemodynamics and the arterial and mixed venous oxygen concentrations remained unchanged. We conclude that inhaled NO following acute massive pulmonary microembolism selectively decreases PAP and PVR without influencing systemic hemodynamics in piglets.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874266     DOI: 10.1378/chest.110.4.1041

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

2.  The effect of a combination of inhaled nitric oxide and an endothelinA-receptor antagonist on hemodynamic dysfunction in experimental acute pulmonary thromboembolism.

Authors:  Ji-Hyun Lee; Sehyun Kim; Byung-Kyu Park; Woo-Sung Kim; Dong-Soon Kim; Won-Dong Kim; Sang-Do Lee
Journal:  Lung       Date:  2005 Mar-Apr       Impact factor: 2.584

3.  Inhaled nitric oxide therapy in adults: European expert recommendations.

Authors:  Peter Germann; Antonio Braschi; Giorgio Della Rocca; Anh Tuan Dinh-Xuan; Konrad Falke; Claes Frostell; Lars E Gustafsson; Philippe Hervé; Philippe Jolliet; Udo Kaisers; Hector Litvan; Duncan J Macrae; Marco Maggiorini; Nandor Marczin; Bernd Mueller; Didier Payen; Marco Ranucci; Dietmar Schranz; Rainer Zimmermann; Roman Ullrich
Journal:  Intensive Care Med       Date:  2005-06-23       Impact factor: 17.440

4.  Increased expired NO and roles of CO2 and endogenous NO after venous gas embolism in rabbits.

Authors:  Per Agvald; L Christofer Adding; Kristofer F Nilsson; Lars E Gustafsson; Dag Linnarsson
Journal:  Eur J Appl Physiol       Date:  2006-04-21       Impact factor: 3.078

5.  Inhaled nitric oxide in patients with pulmonary embolism.

Authors:  J E Tulleken; T S van der Werf; J G Zijlstra; G Capellier; T Jacques; P Balvay; F Barale
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

6.  Increase in exhaled nitric oxide and protective role of the nitric oxide system in experimental pulmonary embolism.

Authors:  K F Nilsson; L E Gustafsson; L C Adding; D Linnarsson; P Agvald
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

Review 7.  How valid are animal models to evaluate treatments for pulmonary hypertension?

Authors:  Maria E Campian; Maxim Hardziyenka; Martin C Michel; Hanno L Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09       Impact factor: 3.000

8.  No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial.

Authors:  Albertus J Kooter; Richard G Ijzerman; Otto Kamp; Anco B Boonstra; Yvo M Smulders
Journal:  BMC Pulm Med       Date:  2010-03-30       Impact factor: 3.317

Review 9.  Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: a report of four patients and review of the literature.

Authors:  Oded Szold; Wisam Khoury; Philippe Biderman; Joseph M Klausner; Pinchas Halpern; Avi A Weinbroum
Journal:  Lung       Date:  2006 Jan-Feb       Impact factor: 2.584

10.  Effect of increasing doses of magnesium in experimental pulmonary hypertension after acute pulmonary embolism.

Authors:  Nikolaus A Haas; Jan Kemke; Ingram Schulze-Neick; Peter E Lange
Journal:  Intensive Care Med       Date:  2004-09-09       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.